RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Price, Quote, News and Overview
NASDAQ:RANI - Nasdaq - US7530181004 - Common Stock - Currency: USD
RANI Quote, Performance and Key Statistics
0.838
-0.24 (-22.41%)
The current stock price of RANI is 0.838 USD. In the past month the price decreased by -20.94%. In the past year, price decreased by -86.72%.
RANI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.45 | 736.32B | ||
| JNJ | JOHNSON & JOHNSON | 15.65 | 378.47B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.25 | 299.86B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.44 | 220.62B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.84 | 217.24B | ||
| MRK | MERCK & CO. INC. | 10.16 | 199.10B | ||
| PFE | PFIZER INC | 7.1 | 129.25B | ||
| SNY | SANOFI-ADR | 13.58 | 127.96B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.49 | 96.91B | ||
| GSK | GSK PLC-SPON ADR | 6.78 | 75.21B | ||
| ZTS | ZOETIS INC | 25.91 | 69.58B | ||
| HLN | HALEON PLC-ADR | 21.96 | 48.52B |
Related stock screener links
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 140
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
What is the stock price of RANI THERAPEUTICS HOLDINGS-A today?
The current stock price of RANI is 0.838 USD. The price decreased by -22.41% in the last trading session.
What is the ticker symbol for RANI THERAPEUTICS HOLDINGS-A stock?
The exchange symbol of RANI THERAPEUTICS HOLDINGS-A is RANI and it is listed on the Nasdaq exchange.
On which exchange is RANI stock listed?
RANI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RANI THERAPEUTICS HOLDINGS-A stock?
11 analysts have analysed RANI and the average price target is 11.22 USD. This implies a price increase of 1238.9% is expected in the next year compared to the current price of 0.838. Check the RANI THERAPEUTICS HOLDINGS-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RANI THERAPEUTICS HOLDINGS-A worth?
RANI THERAPEUTICS HOLDINGS-A (RANI) has a market capitalization of 48.22M USD. This makes RANI a Nano Cap stock.
How many employees does RANI THERAPEUTICS HOLDINGS-A have?
RANI THERAPEUTICS HOLDINGS-A (RANI) currently has 140 employees.
What are the support and resistance levels for RANI THERAPEUTICS HOLDINGS-A (RANI) stock?
RANI THERAPEUTICS HOLDINGS-A (RANI) has a resistance level at 1.07. Check the full technical report for a detailed analysis of RANI support and resistance levels.
Should I buy RANI THERAPEUTICS HOLDINGS-A (RANI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RANI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RANI, evaluating the profitability, health, valuation and growth aspects
- RANI THERAPEUTICS HOLDINGS-A (RANI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RANI THERAPEUTICS HOLDINGS-A (RANI) Sales and EPS estimates to see what analysts future expectations are.
- RANI THERAPEUTICS HOLDINGS-A (RANI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RANI THERAPEUTICS HOLDINGS-A (RANI) Insider and Institutional Ownership to learn about the owners and their transactions.
- RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Chart to make your own analysis
- RANI THERAPEUTICS HOLDINGS-A (RANI) Latest news and press-releases to stay up to date.
Does RANI THERAPEUTICS HOLDINGS-A (RANI) stock pay dividends?
RANI does not pay a dividend.
What is the Price/Earnings (PE) ratio of RANI THERAPEUTICS HOLDINGS-A (RANI)?
RANI THERAPEUTICS HOLDINGS-A (RANI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
What is the Short Interest ratio of RANI THERAPEUTICS HOLDINGS-A (RANI) stock?
The outstanding short interest for RANI THERAPEUTICS HOLDINGS-A (RANI) is 9.57% of its float. Check the ownership tab for more information on the RANI short interest.
RANI Technical Analysis
RANI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RANI. RANI has a bad profitability rating. Also its financial health evaluation is rather negative.
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.94% | ||
| ROE | -1506.93% | ||
| Debt/Equity | 4.83 |
RANI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to RANI. The Buy consensus is the average rating of analysts ratings from 11 analysts.